The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

The results demonstrated a statistically significant fibrosis benefit, which Smith regards as transformational for the field and supportive of ETNB's FGF21 analog, pegozafermin, in NASH.

This article reviews evidence that causally links hormonal disorders with hepatobiliary disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by ...

The company’s lead product candidate, pegozafermin, is currently being developed for the treatment of NASH and SHTG. Allakos is a clinical stage biotechnology company developing therapeutics which ...

Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

The company has recently completed enrollment for its Phase 3 ENTRUST study focused on pegozafermin for severe ... for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases.